Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$0.53
EPS est.
$0.48
EPS surprise
+11.11%
1-day move
-16.36%
Bio-Techne Corporation reported earnings with EPS meeting expectations, but there was no revenue reported against the consensus of $316 million. The stock reacted negatively, dropping 16.36%, likely due to the lack of revenue information and guidance, which may raise concerns among investors about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.53 | $0.53 | +11.11% |
| Revenue | — | $316M | — |
No transcript is on record, and the analysis is based on numerical results only.
Bio-Techne Corporation operates in the health care sector, focusing on life sciences tools and services. The company provides essential products for research and clinical applications, making it a key player in advancing scientific discovery and healthcare solutions.
Last quarter
In Q2-2026, Bio-Techne reported an EPS of $0.46, significantly exceeding expectations by 35.29%. The stock reacted positively, gaining 6.25% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+21.10%
Avg 1-day reaction
-0.91%
Analysts expect Bio-Techne to report solid earnings this quarter, with a consensus EPS of $0.53 and revenue of $316 million. The company has a strong track record of beating earnings estimates.
Bull case
If Bio-Techne exceeds expectations, it could signal robust demand for its products and a strong market position, potentially leading to a significant stock price increase.
Bear case
Conversely, if the company fails to meet earnings expectations, it may raise concerns about growth sustainability and market competition, leading to a negative reaction in the stock.
Key metrics to watch
EPS
0.53Earnings per share is a crucial indicator of the company's profitability and financial health.
Revenue
316MRevenue growth reflects the company's ability to expand its market presence and meet customer demand.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $0.53?
A beat on EPS would reinforce investor confidence in the company's growth trajectory and ability to manage costs effectively.
Q2
What are the revenue expectations for key product lines?
Understanding revenue contributions from specific segments will help gauge market demand and competitive positioning.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may underestimate Bio-Techne's ability to capitalize on emerging market trends in life sciences, leading to stronger-than-expected revenue growth.
Supporting evidence
The company's recent product launches have shown promising early demand.
Historical performance indicates a consistent ability to exceed EPS estimates.
Options pricing suggests heightened volatility, indicating market anticipation of significant news.
Key risk
If revenue from key product lines falls short of expectations, it could challenge the current bullish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance hinges on whether Bio-Techne can maintain its momentum in a competitive market.
Bull confirmed if
An EPS of $0.56 or higher would confirm strong operational performance and market demand.
Bear confirmed if
An EPS below $0.51 would raise concerns about the company's growth prospects.
What the market is pricing for the move.
Implied Move
±9.89%
Historical Avg
±5.8%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.
Options are pricing ±9.2% while TECH has averaged ±5.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
50.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Bio-Techne beats expectations, history suggests a potential stock increase of around 1.96%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of around 1.96%, reflecting concerns about growth and market competitiveness.
The lines on the call that would change the story.